BTZO-1 is primarily used in research settings as a selective agonist for trace amine-associated receptor 1 (TAAR1). It has gained interest for its potential in studying neurological and psychiatric disorders, including schizophrenia, depression, and addiction. Due to its ability to modulate dopaminergic and glutamatergic systems, BTZO-1 serves as a valuable tool in exploring novel therapeutic pathways for these conditions. It is also employed in preclinical studies to investigate the role of TAAR1 in regulating mood, cognition, and psychostimulant effects, offering insights into the development of new central nervous system-targeting drugs.